1

- 1 Co-infection dynamics of SARS-CoV-2 and respiratory viruses in the 2022/2023 respiratory season in
- 2 the Netherlands
- 3 Authors: Gesa Carstens*, Eva Kozanli*, Kirsten Bulsink, Scott McDonald, Mansoer Elahi, Jordy de Bakker,
- 4 Maarten Schipper, Rianne van Gageldonk-Lafeber, Susan van den Hof, Albert Jan van Hoek[†] and Dirk
- 5 Eggink⁺
- 6 *These authors contributed equally
- 7 +Corresponding authors
- 8 Affiliations: Dutch National Institute for Public Health and the Environment (RIVM), Centre for
- 9 Infectious Disease Control (Clb), Bilthoven, The Netherlands
- 10 **Corresponding authors**: Dirk Eggink (dirk.eggink@rivm.nl) and Albert Jan van Hoek
- 11 (albert.jan.van.hoek@rivm.nl)
- 12 Running Title: Co-infections of SARS-CoV-2 with respiratory viruses
- 13
- 14 Highlights
- 15 Our study showed viral co-infections in 11% of the SARS-CoV-2 positive participants
- 16 SARS-CoV-2 mono-infections led to more severe symptoms than the common cold mono-infections
- 17 with seasonal coronavirus or rhinovirus
- 18 SARS-CoV-2 co-infections with common cold viruses did not lead to worse health status compared to
- 19 SARS-CoV-2 mono-infections
- 20 Odds for mono-infection with common cold virus were higher than for co-infection with SARS-CoV-2
- 21 and the respective common cold virus

2

23 Abstract

24 **Objectives:** Evaluation of the presence and effect of SARS-CoV-2 co-infections on disease severity.

25 **Methods:** We collected both symptom data and nose- and throat samples from symptomatic people

during the 2022/2023 respiratory season in a large participatory surveillance study in the Netherlands,

and tested these for 18 respiratory viruses including SARS-CoV-2. We compared reported health status,

28 symptoms and odds of having a mono respiratory viral infection or co-infection with SARS-CoV-2 and

29 another respiratory virus.

30 Results: In total 4,655 samples were included with 22% (n=1,017) testing SARS-CoV-2 positive. Of these

31 11% (n=116) also tested positive for a second respiratory virus. The most frequently occurring co-

32 infections in SARS-CoV-2 positive participants were with rhinovirus (59%; n=69), seasonal coronaviruses

33 (15%; n=17) and adenovirus (7%; n=8). Participants with a co-infection with one of these three viruses

34 did not report more severe disease compared to those with a SARS-CoV-2 mono-infection. The odds of

35 experiencing SARS-CoV-2 co-infection with seasonal coronavirus or rhinovirus were lower compared to

the odds of the respective non-SARS-CoV-2 mono-infection (OR: 0.16, CI 95%: 0.10 – 0.24; OR: 0.21 CI

37 95%: 0.17 – 0.26; respectively).

38 Conclusions: SARS-CoV-2 co-infections with rhinovirus, seasonal coronavirus and adenovirus are 39 frequently observed in the general population, but are not associated with more severe disease 40 compared to SARS-CoV-2 mono-infections. Furthermore, we found indications for inter-virus interaction 41 with rhinovirus and seasonal coronavirus, possibly decreasing risk of co-infection.

42

43 Keywords: Co-infection, mono-infection, SARS-CoV-2, rhinovirus, adenovirus, seasonal coronavirus,

44 viral interference, disease severity, viral load

3

45 INTRODUCTION

The transition of SARS-CoV-2 from pandemic status to endemicity introduced a complex landscape of viral co-circulation, involving not only different SARS-CoV-2 variants but also other respiratory viruses including rhinovirus, influenza virus, adenovirus, respiratory syncytial virus and endemic seasonal coronaviruses. This situation necessitates an examination of prevalence of co-infections, its clinical implications including disease severity, the potential for novel transmission dynamics, and the consequential effects on human susceptibility to a range of viral pathogens.

52 Co-infections involving SARS-CoV-2 and other respiratory viruses have the potential to modify the 53 clinical manifestation of disease. This makes it more difficult to diagnose and treat these patients. For 54 COVID-19 patients, co-infections are seen in some severe cases (1). In addition, it has been suggested 55 that Influenza A and SARS-CoV-2 co-infections are associated with an increased risk for severe disease 56 and death compared to SARS-CoV-2 mono-infection (2).

57 Furthermore, this co-circulation could instigate new inter-virus dynamics, with SARS-CoV-2 infection 58 possibly augmenting or diminishing the susceptibility of individuals to other viral infections, thereby 59 influencing their transmission dynamics (3). There are open questions regarding the implications of this 60 co-circulation for the burden of illness, and whether additional public health measures, such as 61 vaccination programs targeting multiple viruses, might be warranted.

62 To investigate these questions, we conducted a study during the 2022/2023 respiratory season which 63 involved collecting nose and throat swabs by self-sampling from symptomatic individuals in a participatory surveillance cohort in the Netherlands. Samples were tested for SARS-CoV-2 and 18 other 64 65 respiratory viruses using multiplex PCR. This approach resulted in a comprehensive dataset in which the 66 relationships between SARS-CoV-2 and other co-circulating respiratory viruses could be determined, with particular focus on comparisons between SARS-CoV-2 mono-infection and co-infection with a 67 68 second respiratory virus in terms of the severity of illness and the set of presented symptoms, as well as an exploratory assessment of susceptibility to co-infection with specific viruses. Specifically, we 69 70 wished to determine: (i) does SARS-CoV-2 co-infection with another respiratory virus lead to poorer 71 health during the infection (as measured by self-reported health status during the infection episode) 72 compared to the respective mono-infection with another virus or SARS-CoV-2? and (ii) Is there a 73 difference in the odds of infection with other respiratory viruses between participants who tested 74 positive and those who tested negative for SARS-CoV-2?

75

4

77 METHODS

78 Data sources

79 For this study we used a digital participatory surveillance system Infectieradar which was set up in March 80 2020 in the Netherlands as surveillance system for respiratory diseases independent of health care 81 seeking behavior. A rapid antigen self-test and self-sampling component was added to the platform in 82 the season 2022/2023 enabling pathogen identification in symptomatic or SARS-CoV-2 self-test positive 83 participants. The design has been described in detail previously (4, 5). Briefly, upon registration 84 participants fill in an intake questionnaire collecting sociodemographic and medical background data. 85 Subsequently, participants receive weekly questionnaires asking whether they experienced symptoms 86 consistent with an acute respiratory infection (ARI) and whether they had taken a SARS-CoV-2 self-test. 87 Symptomatic participants are asked to perform a SARS-CoV-2 self-test and to answer additional questions regarding their symptoms, healthcare seeking behavior and health status in the previous 88 89 week.

90 A self-sampled nose throat swab (NTS) was requested from a random sample of participants that 91 reported ARI symptoms, i.e. sore throat, cough, runny nose, or dyspnea which had a symptom onset within five days of reporting. The NTS was tested for 18 circulating respiratory viruses. 92

93 Moreover, participants who report symptoms consecutively in more than one weekly questionnaire are

94 asked whether the present symptoms belong to the same infection episodes as the previous symptoms.

95 Therefore, participants can report symptoms and their health status more than once per infection

96 episode and each participant can experience several infection episodes throughout the study period.

97

Inclusion/exclusion criteria 98

99 For this study, we included all participants submitting at least one weekly questionnaire in the respiratory season 2022/2023 (October 1st 2022 to April 30th 2023). Next, swabs were excluded from 100 101 participants who were not invited and did not have ARI symptoms with onset within 5 days of reporting. 102 For the analysis of the self-sampled swabs, only participants submitting an NTS at least once during the 103 study period were included. Participants could have sent in more than one NTS during the study period, 104 but only one NTS per infection episode.

105

106 Laboratory assays/testing methods

107 Laboratory methods have been previously described (4). In short, swabs were collected in virus transport 108 medium and RNA extraction was performed using MagNApure 96 (MP96) (Roche). Extracted RNA was 109 subsequently analyzed for the presence of the following respiratory viruses: SARS-CoV-2, influenza A, 110 influenza B, RSV-A, RSV-B, human metapneumovirus, rhino-/enterovirus, adenovirus, parainfluenza-1, 111 parainfluenza-2, parainfluenza-3, parainfluenza-4, bocavirus, seasonal coronavirus NL63, seasonal

5

coronavirus HKU1, seasonal coronavirus OC43, seasonal coronavirus 229E and MERS-CoV, using SARS CoV-2 specific RT-PCR as described (6) and multiplex real-time PCR (RespiFinder 2SMART, PathoFinder,
 the Netherlands).. Although the Respifinder cannot officially differentiate between rhino-/enterovirus,
 additional in-house typing of a representative subset of samples has shown that the majority of these
 samples are rhinovirus positive. Therefore, in the main text and results we present them as rhinovirus.
 Samples that test positive for only one pathogen by these assays are considered mono-infections.
 Bacterial infections or carriage are not considered for this study.

119

120 Primary outcome variable

121 The main outcome variable was self-reported health status, which was measured in weekly 122 questionnaires. Participants were asked to rate how good or bad their health was in the last week on a 123 scale of 0 to 100, where 100 represented the best imaginable state of health and 0 represented the 124 worst imaginable state of health.

125

126 Exposure variable and covariates

127 The exposure variable was 'infection status' (consisting of: SARS-CoV-2 mono-infection, co-infection 128 SARS-CoV-2 with rhinovirus, co-infection SARS-CoV-2 with adenovirus and co-infection SARS-CoV-2 with 129 seasonal coronaviruses). The following baseline characteristics were included as covariates in 130 multivariable analysis: sex, age-group (<30, 30-39, 40-49, 50-64; 65+ years), education level 131 (none/primary only, middle, higher (i.e., university qualification)), presence of children aged <5 years in 132 the household, presence of children aged 5-18 years in the household (both binary variables), smoker 133 status (non-smoker, ever-smoker), hay fever and/or other allergies and regular use of medication for selected underlying conditions (lung disease (e.g., emphysema, COPD), cardiovascular disease, diabetes; 134 135 all coded as binary variables).

136

137 **Descriptive analysis**

We report the observed distribution over the various detected respiratory viruses within our analysis period, and graphically show the temporal characteristics of the detected mono- and co-infections. We describe the distribution of reported symptoms (both ARI symptoms and other possible symptoms), comparing SARS-CoV-2 mono-infection, SARS-CoV-2 co-infection with rhinovirus, co-infection with adenovirus, co-infection with seasonal coronaviruses, and mono-infections with rhinovirus, adenovirus, and seasonal coronaviruses. Reported symptoms from more than one weekly questionnaire per infection episode were pooled.

6

146 Association between participant characteristics and self-reported health status

147 We performed univariable and multivariable analyses to estimate differences in self-reported health status among all symptomatic individuals within this study population. For this, we used a generalized 148 149 linear mixed effects model. We incorporated a random intercept for participant ID to account for 150 variation within participants and added a natural spline with three knots to account for time difference 151 between symptom onset and submitting a weekly questionnaire capturing potential variations in health 152 status over the disease course. The multivariable regression model was adjusted for all demographic and comorbidity variables as previously specified. 153

154

Comparison of reported health status between mono- and co-infections with SARS-CoV-2 and 155 156 respiratory viruses

157 We used the same generalized linear mixed effects model to estimate the differences in self-reported 158 health status among mono- and coinfected individuals. Based on this, to visually compare the 159 associations of mono-infection and co-infections with SARS-CoV-2 and rhinovirus, adenovirus or 160 seasonal coronaviruses on the health status adjusted for confounders we computed and plotted 161 estimated-marginal means for the health status using the emmeans package (7). Next, we plotted the 162 marginal mean of the health status over time since symptom onset and stratified by age group for the 163 different mono- and co-infections to visually show the progression of the health status during infection.

In an alternative analysis, we analyzed only the lowest reported health status per participant infection 164 episode across mono- and co-infected persons to compare differences in perceived health during the 165 166 as most severe experienced phase of the infection.

167 **Exploratory assessment of viral load**

168 To study the possible association between viral load of SARS-CoV-2 mono-infections and co-infections, 169 we performed a linear regression model with Ct value as outcome variable and infection status as 170 independent variable with SARS-CoV-2 mono-infection as reference group. We performed univariate 171 and multivariate analyses, the latter corrected for age group and sex.

172

173 Symptom analysis

174 We performed multiple multivariable logistic regressions to assess the odds of experiencing various 175 respiratory or constitutional symptoms in case of a non-SARS-CoV-2 mono-infection or SARS-CoV-2 co-

7

infection, using SARS-CoV-2 mono-infection as reference group. The analyses were adjusted for agegroup and sex.

178

179 Exploratory assessment of co-infection prevalence associated with SARS-CoV-2

We conducted multiple logistic regression analyses for infection with the most common monoinfections; those with rhinovirus or with one of the seasonal coronaviruses. We compared the odds of testing positive for either virus between participants who tested positive and those who tested negative for SARS-CoV-2. The estimated odds ratio (OR) for co-infection with another virus can be interpreted as the association of SARS-CoV-2 infection on susceptibility to that other virus and vice versa. This analysis is necessarily exploratory because other, unmeasured factors could influence the odds of co-infection (e.g., respiratory virus seasonality, and SARS-CoV-2 or influenza vaccination effectiveness).

- 187 All analyses were conducted using R statistical software, version 4.3.1 (8).
- 188

189 **RESULTS**

190 Participants and Sample collection

- 191 Within the analysis period (1 Oct 2022 through 30 April 2023), a total of 17,499 participants took part
- in the *Infectieradar* self-swab study (Fig. S1). Of these, 12,968 (74%) reported ARI symptoms in at least
- one weekly survey within 5 days of symptom onset, of which 3,498 (27%) reported a positive self-test
- 194 (Table 1). In total 4,689 NTS samples from 3,945 participants were included in this study and presence
- 195 of SARS-CoV-2 as well as other respiratory viruses was investigated.
- 196 Our study population had a higher proportion of females (57.2%) than males with the largest age group
- being 50-64 years (Table 1). The youngest age group (<25) was underrepresented with only 3.3%. The
- 198 majority of our participants have completed higher education (59%).
- 199
- 200 **Table 1**. Characteristics of the Infectieradar study population and linked laboratory database.

Variable	Eligible Participants N (%)	Self-swabs sent in N (%)	Detections SARS-CoV-2 N (%)	Health status Median [IQR]	No. symptoms Median [IQR]
(Samples)	-	4,655	1,028	-	-
Infection status					
No infection	-	1,761 (38%)	-	71 [60, 81]	3 [2, 5]
SARS-CoV-2 mono-infection	-	907 (19%)	912 (89%)	63 [50, 75]	6 [4, 9]
Rhinovirus mono-infection	-	911 (20%)	-	70 [60, 81]	4 [2, 5]
Adenovirus mono-infection	-	25 (0.5%)	-	74 [64, 90]	3 [2, 6]

Seasonal coronaviruses mono-infection	-	329 (7%)	-	70 [58, 80]	4 [2, 5]
Co-infection SARS-CoV-2 and rhinovirus	-	69 (1.5%)	69 (6.7%)	65 [50 <i>,</i> 75]	5 [3, 7]
Co-infection SARS-CoV-2 and adenovirus		8 (0.2%)	8 (0.8%)	60 [49, 70]	5 [3, 8]
Co-infection SARS-CoV-2 and seasonal coronaviruses	-	17 (0.4%)	17 (1.7%)	64 [51, 72]	5 [4, 7]
(Participants)	17,069	3,921	1,017		
Sex					
Female	9,748 (57%)	2,547 (65%)	638 (63%)	69 [53, 80]	4 [2, 6]
Male	7,289 (43%)	1,368 (35%)	377 (37%)	70 [57, 80]	4 [4, 7]
Age-group					
<25 yrs	486 (2.8%)	115 (2.9%)	21 (210%)	63 [50, 75]	5 [3, 8]
25-39 yrs	2,270 (13%)	672 (17%)	152 (15%)	67 [54, 78]	4 [3, 7]
40-49 yrs	2,727 (16%)	739 (19%)	192 (19%)	68 [51, 80]	4 [2, 6]
50-64 yrs	6,660 (39%)	1,519 (39%)	390 (38%)	70 [50, 80]	4 [2, 7]
65+ yrs	4,926 (29%)	876 (22%)	262 (26%)	70 [50, 84]	4 [2, 6]
Education level					
Lower/none	290 (1.7%)	44 (1.1%)	19 (1.9%)	70 [51, 80]	5 [3, 7]
Middle	6,583 (39%)	1,369 (35%)	386 (38%)	70 [54, 80]	4 [2, 7]
Higher	9,999 (59%)	2,469 (64%)	595 (60%)	70 [55, 80]	4 [2, 6]
Ever smoker	1,586 (9.3%)	288 (7.4%)	89 (8.8%)	69 [53 <i>,</i> 80]	4 [3, 7]
Underlying condition					
Allergy(s)/hay fever	6,021 (35%)	1,536 (39%)	365 (36%)	68 [55, 80]	4 [2, 7]
Diabetes	686 (4.0%)	108 (2.8%)	26 (2.6%)	72 [56, 82]	4 [2, 5]
Chronic lung disease	457 (2.7%)	74 (1.9%)	22 (2.2%)	61 [50, 75]	4 [3, 7]
Cardiovascular disease	1,679 (9.8%)	313 (7.9%)	93 (9.1%)	69 [50, 80]	4 [2, 6]
Household composition					
1+ children <5 years	1,255 (7.4%)	356 (9.1%)	86 (8.5%)	70 [59, 80]	4 [2, 6]
1+ children 5-18 years	3,764 (22%)	968 (25%)	247 (24%)	68 [52, 80]	4 [2, 6]

Note. Participants can have more than one infection during the study period. CI = confidence interval. Health status and number of symptoms for the different participant characteristics are shown only for participants who sent in a nose- and throat swab.

201

202

203 Pathogen detection

204 1,028 (22%) of samples were SARS-CoV-2 positive measured by SARS-CoV-2 specific RT-PCR. Co-205 infection with at least one other respiratory virus was detected in 11% (116/1,028) of SARS-CoV-2 206 positive samples. The most frequently occurring co-infections in SARS-CoV-2 positive participants were 207 rhinovirus (59%; 69/116), seasonal coronaviruses (15%; 17/116), adenovirus (7%, 8/116) or other 208 viruses (Table S1) (20%; 22/116, consisting of influenza A (2/22), influenza B (2/22), bocavirus (2/22), parainfluenza virus (5/22), respiratory syncytial virus (6/22) and human metapneumovirus (5/22)). The 209 210 corresponding percentages of samples with detected mono-infection were SARS-CoV-2 (19%;

9

- 211 912/4,689), rhinovirus (20%; 923/4,689), adenovirus (0.5%; 25/4,689), and seasonal coronaviruses (7%;
- 212 329/4,689).
- 213 Co-infections coincided with their respective mono-infection, as shown in Figure 1A and 1B, in which
- the mono- and co-infections are plotted during the 2022/2023 season.
- 215



216

Figure 1. Detected respiratory infections during the 2022/2023 respiratory season in Infectieradar in the Netherlands. Detected mono-infections (A) and co-infections (B) over the analysis period (1 Oct 2022 – 30 April 2023).

220

221 Health status and covariates in the Infectieradar population

Reported health status was analyzed for the symptomatic study population. Most participants reported
a health status higher than 50 out of 100 with only slight differences between sex (Fig. S2). We assessed

the association between various covariates and self-reported health status by estimating beta

10

225 coefficients in both univariable and multivariable regression analyses (Fig. 2 and Table S2). The male sex 226 was associated with reporting a higher health status (adjusted beta: 0.17, 95% CI 0.13 to 0.2), as can be 227 seen in Figure 2. Also, age was associated with health status: compared to participants aged 50-64 years, 228 participants of age group <25 and 25-39 were associated with reporting a lower health status (adjusted 229 beta -0.13, 95% CI -0.22 to -0.04 and adjusted beta -0.13, 95% CI -0.18 to -0.08, respectively) while 230 participants of the age group 65+ reported a higher health status (adjusted beta 0.11, 95% CI 0.07 to 231 0.14). Moreover, participants with allergies and/or hay fever were associated with a lower health status 232 (adjusted beta -0.08, 95% CI -0.11 to -0.05) as well as participants with diabetes (adjusted beta -0.1, 95% 233 CI -0.19 to -0.02) and heart conditions (adjusted beta -0.17, 95% CI -0.23 to -0.12).

234





Figure 2: Forest plot of beta coefficients of the linear regression model estimating the association
 between main participant characteristics with health status during infection. Results of univariable
 and multivariable regression analyses for all symptomatic participants of our study population with 95%
 confidence interval.

- 240
- 241

242 Comparison self-reported health status between mono- and co-infected participants

243 Using the results of all pathogen detections, we estimated the effect of having a mono-infection with

244 SARS-CoV-2, adenovirus, rhinovirus and seasonal coronaviruses and having SARS-CoV-2 co-infections

with one of those viruses on perceived health status during infection (Table S3). Figure 3 shows the

estimated marginal mean of the health status of each infection. The mean health status was statistically

11

- significantly higher for participants with a mono-infection with rhinovirus, seasonal coronaviruses or
 adenovirus than for those with a SARS-CoV-2 mono-infection, suggesting more severe disease during
 COVID-19 compared to more traditional respiratory viruses (often referred to as common cold viruses).
 Interestingly, participants with a co-infection of one of these common cold viruses with SARS-CoV-2 had
 a similar mean health status compared to participants with a SARS-CoV-2 mono-infection.
- 252
- 253
- 254
- 255



256

Figure 3: Mean health status during infection. Estimated marginal means of health status and 95%
 Confidence level per infection. Horizontal line indicating the estimated-marginal mean health status for
 participants with SARS-CoV-2 mono-infection infection.

260

261

Additionally, we observed that the estimated marginal mean health status varies over time depending on the day since symptom onset (Fig. S3). Across all age groups and infections, the lowest health is reported around day 4-6 since symptom onset before gradually increasing again, with older age groups consistently reporting a higher health status during the whole infection episode compared to the lowest age group. Due to the change in health status during disease progression we adjusted the main analysis and performed an alternative analysis.

In this alternative analysis, we investigated the lowest reported health status per infection episode instead of the mean health status in the model to compare severity during the most severe phase of different infections as perceived by the participants (n = 4,950) instead of the health status over the complete episode. All trends determined in the main analysis were similar in this analysis (Fig. 4 and

- 12
- Table S4). Overall, we found SARS-COV-2 cases more severe disease than traditional common cold
- viruses, however SARS-CoV-2 co-infections do not cause worse health status compared to SARS-CoV-2
- 274 mono-infections.





Figure 4. Results of the alternative analysis using only the lowest health status per infection period as
 model input. Estimated marginal means of the health status with 95% Confidence level per infection.
 Horizontal line indicating the estimated-marginal mean health status for participants with SARS-CoV-2
 mono-infection infection.

281

282 As no difference in disease severity was observed between SARS-CoV-2 mono-infections and co-283 infections, it is interesting to investigate the effect of a co-infection on SARS-CoV-2 viral load. Viral load 284 has been related to disease severity before (9). And in addition, viral load might influence the risk of co-285 infection. We therefore compared Ct values as a proxy of viral load between SARS-CoV-2 mono-286 infections and co-infections. Mono-infections of SARS-CoV-2 are associated with a significantly lower Ct 287 value (p value <0.01), reflecting higher viral load, as compared to co-infections with rhinovirus and SARS-288 CoV-2 (mean Ct value: 22.3 and 24.0, respectively, Table S5). We could not confirm higher Ct values for 289 SARS-CoV-2 co-infections with adenovirus and coronaviruses (mean Ct value: 21.6 and 24.3, 290 respectively), likely caused by a lower number of cases.

291

292 Difference in symptoms between mono- and co-infected individuals

The median number of reported different symptoms of participants with SARS-CoV-2 mono-infection was 6 [Interquartile range (IQR): 4-9], which was higher than reported by participants with other monoinfections (rhinovirus: 4 [IQR 2-5]; adenovirus: 3 [IQR 2-6]; seasonal coronaviruses: 4 [IQR 2-5]) and co-

13

296 infections (co-infection SARS-CoV-2 with rhinovirus: 5 [IQR 3-7]; co-infection SARS-CoV-2 with 297 adenovirus: 5 [IQR 3-8]; co-infection SARS-CoV-2 with seasonal coronaviruses: 5 [IQR 4-7], Table 1). In 298 line with this, 40% (n = 365) of the participants with SARS-CoV-2 mono-infection took sick leave, while 299 sick leave was significantly less common among participants with other mono-infections (11% (n = 97),p-value <0.001 for rhinovirus; 16% (n = 4), p-value 0.01 for adenovirus; and 10% (n = 32), p-value < 0.001 300 301 for seasonal coronavirus; Table S6). However, SARS-CoV-2 co-infected participants took sick leave 302 significantly more often than their mono-infected non-SARS-CoV-2 counterparts but not more than participants with SARS-CoV-2 mono-infection (rhinovirus co-infection: 33% (n = 23), p-value 0.31; 303 adenovirus co-infection: 63% (n = 5), p-value 0.28; seasonal coronavirus co-infection: 35% (n = 6), p-304 305 value 0.81).

- 306 Of the participants mono-infected with SARS-CoV-2, 87% reported rhinitis, as well as all participants co-
- 307 infected with adenovirus (100%) and 94% of participants co-infected with seasonal coronaviruses (Fig.
- 308 5). Cough, a sore throat and sneezing were also reported frequently by most participants. Compared to
- 309 SARS-CoV-2 mono-infection, the odds of experiencing respiratory or constitutional symptoms were
- 310 mainly similar for SARS-CoV-2 co-infected participants (Fig. S4). However, SARS-CoV-2 and rhinovirus
- 311 co-infected individuals had slightly lower odds of experiencing headache, sneeze, pain and chills.
- 312

medRxiv preprint doi: https://doi.org/10.1101/2024.09.10.24313400; this version posted September 10, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

	wateryeye -	79(8.7%)	2 (25.0%)	2 (8.0%)	4 (5.8%)	55 (6.0%)	0(0.0%)	23 (7.0%)
	vomiting -	12(1.3%)	0(0.0%)	0(0.0%)	1(1.4%)	12(1.3%)	0(0.0%)	8 (2.4%)
	sputum -	80 (8.8%)	0(0.0%)	3 (12.0%)	2 (2.9%)	67 (7.4%)	1 (5.9%)	20(6.1%)
	sorethroat -	607 (66.9%)	4 (50.0%)	19 (76.0%)	43 (62.3%)	649 (71.2%)	10 (58.8%)	197 (59.9%)
	sneeze -	606 (66.8%)	7(87.5%)	6 (24.0%)	33 (47.8%)	545 (59.8%)	13 (76.5%)	200 (60.8%)
	rhino -	785(86.5%)	8 (100.0%)	13 (52.0%)	56 (81.2%)	778 (85.4%)	16 (94.1%)	278 (84.5%)
	pain -	356 (39.3%)	3 (37.5%)	7(28.0%)	18 (26.1%)	99 (10.9%)	3(17.6%)	43 (13.1%)
	nosebleed -	23 (2.5%)	0(0.0%)	1(4.0%)	2 (2.9%)	20 (2.2%)	0(0.0%)	7(2.1%)
_	no_taste -	117 (12.9%)	1 (12.5%)	1(4.0%)	7(10.1%)	22(2.4%)	1(5.9%)	10 (3.0%)
mptor	no_smell -	129 (14.2%)	1 (12.5%)	1(4.0%)	7 (10.1%)	18 (2.0%)	0(0.0%)	7(2.1%)
Reported Syr	nausea -	90 (9.9%)	0(0.0%)	0(0.0%)	5(7.2%)	41 (4.5%)	0(0.0%)	19 (5.8%)
	headache -	565 (62.3%)	3 (37.5%)	9(36.0%)	34 (49.3%)	316 (34.7%)	10 (58.8%)	142 (43.2%)
	fever -	327 (36.1%)	2 (25.0%)	3 (12.0%)	17 (24.6%)	80 (8.8%)	5 (29.4%)	28 (8.5%)
	dyspnea -	262 (28.9%)	3 (37.5%)	5 (20.0%)	20 (29.0%)	143 (15.7%)	3(17.6%)	48 (14.6%)
	diarrhea -	41 (4.5%)	0(0.0%)	0(0.0%)	3(4.3%)	10(1.1%)	0(0.0%)	6(1.8%)
	cough -	729 (80.4%)	6 (75.0%)	15 (60.0%)	50 (72.5%)	544 (59.7%)	14 (82.4%)	191 (58.1%)
	chills -	393 (43.3%)	2 (25.0%)	7(28.0%)	21(30.4%)	114 (12.5%)	6 (35.3%)	45 (13.7%)
	chestpain -	91 (10.0%)	1 (12.5%)	2(8.0%)	3(4.3%)	24 (2.6%)	1(5.9%)	5(1.5%)
	asthenia -	475 (52.4%)	3 (37.5%)	9 (36.0%)	30 (43.5%)	245(26.9%)	8 (47.1%)	88 (26.7%)
	anorexia -	190 (20.9%)	2 (25.0%)	3 (12.0%)	11 (15.9%)	46 (5.0%)	1(5.9%)	16 (4.9%)
	abdopain -	65 (7.2%)	0(0.0%)	2(8.0%)	4 (5.8%)	29 (3.2%)	0(0.0%)	14 (4.3%)
		SARS-CoV-2 Infection	Co-infection SARS-CoV-2 and adenovirus	Adenovirus Infection	Co-infection SARS-CoV-2 and Rhinovirus	Rhinovirus Infection	Co-infection SARS-CoV-2 and seasonal Coronavirus	Seasonal Coronavirus Infection

Percentage reported symptom

14



0

_

Figure 5: Overview of symptom prevalence. Percentage reported symptoms per infection (SARS-CoV-2 mono-infection, SARS-CoV-2 co-infection with adenovirus, co-infection with rhinovirus, co-infection with seasonal coronaviruses, and mono-infection with rhinovirus, adenovirus, and seasonal coronaviruses) among all participants with lab samples (*n*=3,963). Numbers in the heatmap correspond to N (%). Colored boxes indicate symptoms that are significantly less reported (blue boxes) compared to the reference group SARS-CoV-2 mono-infection (black box). There were no symptoms which were significantly more often reported compared to the reference group.

- 321
- 322

323 Exploratory assessment of co-infection prevalence associated with SARS-CoV-2

Next, we investigated whether infection with SARS-CoV-2 did alter the odds of infection with another

respiratory virus (Fig. 6). Odds for co-infection with SARS-CoV-2 combined with either seasonal

326 coronavirus or rhinovirus are lower than mono-infection with one of these non-SARS-CoV-2 viruses (OR:

15

- 327 0.16, CI 95%: 0,10 to 0.24, n = 17; OR: 0.21, CI 95%: 0.17 to 0.24, n = 69; respectively). The number of
- 328 adenovirus co-infections was too low to perform this analysis on.
- 329



330 331 Figure 6: Odds ratio for co-infection with SARS-CoV-2 and other pathogens compared to SARS-CoV-2 332 mono-infection. The plot shows odds ratios for co-infection with seasonal coronavirus (n=17) and rhinovirus (n=69). 333

334

335

336 DISCUSSION

337 We examined the associations between respiratory mono-infections and co-infections with SARS-CoV-2, and reported symptoms and perceived health in the Netherlands during the transition of SARS-CoV-338 339 2 from a pandemic to an endemic virus. Co-infection of SARS-CoV-2 with another respiratory virus was 340 found in 11% of SARS-CoV-2 positive participants; these co-infections included mainly rhinovirus, 341 seasonal coronaviruses and adenovirus. Compared with SARS-CoV-2 mono-infection, participants' self-342 reported health status for a mono-infection with these three common cold viruses was higher, 343 suggesting less severe disease. However, a co-infection of SARS-CoV-2 with these three common cold 344 viruses resulted in a similar health status compared to SARS-CoV-2 mono-infection . Across all monoand co-infections similar symptoms were reported with rhinitis, cough, sore throat and sneezing being 345 346 the most frequent symptoms. However, SARS-CoV-2 and rhinovirus co-infected individuals had lower 347 odds of experiencing headache, sneeze, pain and chills than individuals infected only with SARS-CoV-2.

16

349 A meta-analysis of studies reporting co-infection of SARS-CoV-2 with other respiratory viruses up to 350 August 2021 found a pooled co-infection prevalence of 5.01% (95% CI 3.34%–7.27%) among those with SARS-CoV-2 (10). This is lower than the 11% we found in our study. However, our study period took 351 352 place between October 2022 and May 2023. During this period, there was a higher circulation of SARS-353 CoV-2 (with omicron variants) (11) compared to the period before August 2021. Also, there were fewer 354 nonpharmaceutical interventions such as facemasks and social distancing measures in place, leading to 355 heightened circulation of all respiratory viruses and thus to a higher probability of (co-)infection (12). 356 This highlights the impact of temporal fluctuations and co-circulation of respiratory viruses on co-357 infection rates, which may vary across different periods and geographic locations.

358 Interestingly, we observed low numbers of co-infections with influenza. Unlike the findings from a study 359 in Missouri, USA conducted between October 2021 and January 2022, in which a prevalence of 33% was reported for influenza co-infection among persons with SARS-CoV-2 (13). Even though in the 360 361 Netherlands the 2022/2023 influenza season lasted until approximately week 11 (i.e., 13-19 March 362 2023) (11) we detected 110 Influenza mono-infections and only 4 influenza and SARS-CoV-2 co-363 infections (Table S1).

364 There is limited literature on SARS-CoV-2 co-infections among those who do not seek health care. A 365 meta-analysis, in which the vast majority of included studies had been conducted among adult-patients 366 hospitalized for SARS-CoV-2, found an increased odds of mortality (OR=2.84; 95% CI: 1.42-5.66) 367 associated with bacterial, fungal or viral co-infection (14). This increase in severity in SARS-CoV-2 co-368 infected patients compared to mono-infected patients is not confirmed with our results. We observed 369 that co-infected individuals reported a similarly perceived health status compared to participants mono-370 infected with SARS-CoV-2, with a point estimate which indicates slightly less severe disease. However, 371 we only included co-infections with respiratory common cold viruses, and did not test for many bacteria 372 and fungi. Therefore, some of those labeled as SARS-CoV-2 mono-infections could have been co-373 infected with one of those untested pathogens. Additionally, we observed that viral loads were lower 374 in co-infected individuals, which could have influenced why the health status was not more severe for 375 SARS-CoV-2 co-infections compared to SARS-CoV-2 mono-infections. Furthermore, these lowered viral 376 loads in the co-infection group could be an indication for inter-virus interaction.

377

348

378 In our exploratory analysis, we observed lower odds of experiencing SARS-CoV-2 co-infections with both 379 seasonal coronaviruses and rhinovirus compared to experiencing mono-infection with those non-SARS-380 CoV-2 viruses. Seasonality of viruses might affect how much co-circulation of different respiratory

17

381 viruses occurs and therefore also affects the number of co-infections with these viruses and SARS-CoV-382 2. A lack of co-circulation or co-infection between respiratory viruses can suggest interaction, i.e. 383 competition for susceptible hosts between those viruses or internal seasonality of those viruses (15). 384 During our study period in the respiratory season (October to May) we observed co-circulation of the 385 compared respiratory viruses with SARS-CoV-2 indicating the possibility of co-infections. However, our 386 exploratory assessment of the odds of SARS-CoV-2 co-infection indicates that we observed fewer cases 387 than expected based on the prevalence of the non-SARS-CoV-2 respiratory viruses. This finding could 388 suggest virus-virus interplay between SARS-CoV-2 and rhinovirus as well as seasonal coronaviruses. For other pathogens numbers were too low to assess this in this study. 389

390 However, without knowing the timing of infection of the viruses in the host and the subsequent immune 391 response, it is difficult to understand the underlying mechanisms that influence SARS-CoV-2 interplay 392 with other respiratory viruses. Viral interference is often proposed as a cause for this interplay in which 393 case presence of one virus could inhibit entrance or replication of the other virus through mechanisms 394 of the virus itself, or of its host. Cellular overlap and for example use of similar receptors for cell entry 395 could affect co-infection rates (16, 17). Furthermore, it was previously suggested that as host innate 396 immunity, including interferon response, increases upon the first infection, susceptibility for a second 397 infection is altered (18). Previous studies have shown that the presence of rhinovirus in the respiratory 398 endothelium can block SARS-CoV-2 viral replication (19), while SARS-CoV-2 primary infection was shown 399 to not impact rhinovirus replication (20). Evidence for the interplay between seasonal coronaviruses 400 and SARS-CoV-2 is less clear: several studies have suggested that cross-immunity exists for SARS-CoV-2 401 and seasonal coronaviruses (17, 21), while other studies found increased SARS-CoV-2 infection 402 susceptibility and increased disease severity associated with pre-existing immunity for seasonal 403 coronaviruses (22). Although these interplays are likely to explain the reduced odds of SARS-CoV-2 coinfection with seasonal coronaviruses or rhinovirus, a simplistic model can hardly capture these 404 405 dynamics. More intricate models require more information on the timing and dynamics of infections 406 and host responses to define virus interactions. Adding to the theory of viral interference, we observed 407 that co-infections of SARS-CoV-2 and rhinovirus have lower viral load than SARS-CoV-2 mono-infection. 408 This could mean that the presence of one virus could obstruct the susceptibility or efficient replication 409 of another virus. However, these findings should be further investigated to confirm viral interference. 410 To further explore this, in vitro studies might be more appropriate or cohort studies using dense 411 sampling allowing detection of viral dynamics, including low viral loads of co-infections. Additionally, 412 future work using sequential sampling could focus on the implications of the order of infection on the 413 susceptibility to acquire co-infection.

18

In this study, we found that less people called sick with a mono-infection compared to those with a co-414 415 infection of these same viruses with SARS-CoV-2. This observation does not support an effect of 416 behavior, in the form of isolation, on co-infection susceptibility, as mono-infected individuals are not more isolated than co-infected individuals. Moreover, we observed more sick leave for SARS-CoV-2 417 418 mono-infections as compared to other mono-infections. This suggests that SARS-CoV-2 infected 419 individuals may have experienced more severe disease, as also indicated by the reported health status. 420 However, as people had a self-test result, previous advice to stay at home when being infected, likely 421 also affected behavior.

422

423 The main strength of this study is the community-based population consisting of voluntary participants 424 from the Infectieradar surveillance system who self-tested for SARS-CoV-2 and present with mild 425 symptoms. Due to the weekly questionnaires and self-sampling, we were able to catch infections in an 426 early phase of the disease and collect information on perceived health and symptoms during the 427 infection. Potential limitations concern representativeness: compared with the general population, Infectieradar participants are more likely to be female, ages 50-64 years are over-represented, and are 428 429 more highly educated and have lower prevalence of underlying health problems (5). Moreover, we 430 cannot estimate the role of behavior in co-infection prevalence. Self-reporting introduces biases in perceived health status and could lead to missing cases because of more severe diseases being not 431 432 reported in Infectieradar. Furthermore, studying individuals with ARI symptoms can introduce selection 433 bias, as viral status and viral load may affect the probability of symptoms and consequently the 434 likelihood of individuals being included in the study population (23). Therefore, our observed odds ratios of SARS-CoV-2 co-infections might not reflect the full population-level interactions between SARS-CoV-435 436 2 and other respiratory viruses due to unknown selection probabilities.

437

In conclusion, we show that, within a cohort of the general population in the Netherlands in the respiratory season of 2022 to 2023, SARS-CoV-2 co-infections with rhinovirus, seasonal coronavirus and adenovirus did not lead to a worse perceived disease severity compared to SARS-CoV-2 monoinfections. In our study the odds of experiencing SARS-CoV-2 co-infection with rhinovirus and seasonal coronaviruses were lower than for experiencing the respective non-SARS-CoV-2 mono-infections, suggesting a form of viral interference.

445 **Competing interests**

- 446 All authors of this manuscript declare no competing interests.
- 447

448 **Ethics**

449 The samples were collected as part of *Infectieradar*. The protocol for *Infectieradar* was approved by the 450 Medical Ethics Review Committee Utrecht (reference number: WAG/avd/20/008757; protocol 20-131) 451 was obtained given the nature of data collection. All participants provided informed consent upon 452 registration, which included agreement to the privacy statement and described the processing of 453 personal data and research results, website security measures taken, and how to file a complaint. 454 Participants were eligible to withdraw from the study at any time. Individuals had to be 16 years or over 455 to be able to participate.

456

Funding: 457

458 This work was supported by the ministry of Health, Welfare and Sports (VWS), the Netherlands. The 459 funders had no role in study design, data collection and analysis, decision to publish, or preparation of 460 the manuscript.

461

462 Acknowledgements:

463 We thank the participants of Infectieradar for their weekly contributions and submission of samples. 464 Without their contribution this project won't have been a success. Furthermore, we thank our 465 colleagues who help to maintain and run the Infectieradar-cohort and handling the samples. Developing 466 and running this study has been a huge team effort.

medRxiv preprint doi: https://doi.org/10.1101/2024.09.10.24313400; this version posted September 10, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

467 **REFERENCES**

Zhu X, Ge Y, Wu T, Zhao K, Chen Y, Wu B, et al. Co-infection with respiratory pathogens among
 COVID-2019 cases. Virus Research. 2020;285:198005.

Yan X, Li K, Lei Z, Luo J, Wang Q, Wei S. Prevalence and associated outcomes of coinfection
between SARS-CoV-2 and influenza: a systematic review and meta-analysis. International Journal of
Infectious Diseases. 2023;136:29-36.

Wong A, Barrero Guevara LA, Goult E, Briga M, Kramer SC, Kovacevic A, et al. The interactions
 of SARS-CoV-2 with cocirculating pathogens: Epidemiological implications and current knowledge gaps.
 PLoS Pathogens. 2023;19(3):e1011167.

- Smit T, Carstens G, Han W, Bulsink K, Bakker Jd, Elahi M, et al. Flexible and scalable participatory
 syndromic and virological surveillance for respiratory infections: our experiences in The Netherlands.
 medRxiv. 2024:2024.04.24.24306278.
- 479 5. McDonald S, Wijngaard Cvd, Wielders C, Friesema I, Soetens L, Paolotti D, et al. Risk factors
 480 associated with the incidence of self-reported COVID-19-like illness: data from a web-based syndromic
 481 surveillance system in the Netherlands. Epidemiology & Infection. 2021;149:e129.
- 482 6. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel
 483 coronavirus (2019-nCoV) by real-time RT-PCR. Eurosurveillance. 2020;25(3):2000045.
- 484 7. Lenth RV. emmeans: Estimated Marginal Means, aka Least-Squares Means 2024 [Available
 485 from: <u>https://github.com/rvlenth/emmeans</u>.
- 486 8. R Core Team. R: A Language and Environment for Statistical Computing. 4.3.1 ed: R Foundation
 487 for Statistical Computing; 2023.
- 488 9. Munker D, Osterman A, Stubbe H, Muenchhoff M, Veit T, Weinberger T, et al. Dynamics of SARS489 CoV-2 shedding in the respiratory tract depends on the severity of disease in COVID-19 patients. Eur
 490 Respir J. 2021;58(1).
- 491 10. Krumbein H, Kümmel LS, Fragkou PC, Thölken C, Hünerbein BL, Reiter R, et al. Respiratory viral
 492 co-infections in patients with COVID-19 and associated outcomes: A systematic review and meta493 analysis. Reviews in Medical Virology. 2023;33(1):e2365.
- Reukers D, van Asten L, Hooiveld M, Jongenotter F, de Lange M, Teirlinck A, et al. Surveillance
 of acute respiratory infections in the Netherlands: winter 2022/2023. SARS-CoV-2, influenza virus, RSV
 and other respiratory viruses. Surveillance van acute luchtweginfecties in Nederland: winter 2022/2023:
 Rijksinstituut voor Volksgezondheid en Milieu RIVM; 2023.
- 498 12. Olsen SJ, Winn AK, Budd AP, Prill MM, Steel J, Midgley CM, et al. Changes in Influenza and Other
 499 Respiratory Virus Activity During the COVID-19 Pandemic United States, 2020-2021. MMWR Morb
 500 Mortal Wkly Rep. 2021;70(29):1013-9.
- Tang CY, Boftsi M, Staudt L, McElroy JA, Li T, Duong S, et al. SARS-CoV-2 and influenza coinfection: A cross-sectional study in central Missouri during the 2021–2022 influenza season. Virology.
 2022;576:105-10.
- Musuuza JS, Watson L, Parmasad V, Putman-Buehler N, Christensen L, Safdar N. Prevalence and
 outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: A systematic review
 and meta-analysis. PloS one. 2021;16(5):e0251170.
- 507 15. Eldesouki RE, Uhteg K, Mostafa HH. The circulation of Non-SARS-CoV-2 respiratory viruses and
 508 coinfections with SARS-CoV-2 during the surge of the Omicron variant. Journal of Clinical Virology.
 509 2022;153:105215.
- 510 16. Jackson CB, Farzan M, Chen B, Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nature
 511 Reviews Molecular Cell Biology. 2022;23(1):3-20.
- 512 17. Liu D, Chen C, Chen D, Zhu A, Li F, Zhuang Z, et al. Mouse models susceptible to HCoV-229E and
 513 HCoV-NL63 and cross protection from challenge with SARS-CoV-2. Proceedings of the National Academy
 514 of Sciences. 2023;120(4):e2202820120.
- 515 18. Domenech de Cellès M, Goult E, Casalegno J-S, Kramer SC. The pitfalls of inferring virus–virus 516 interactions from co-detection prevalence data: application to influenza and SARS-CoV-2. Proceedings
- 517 of the Royal Society B. 2022;289(1966):20212358.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Dee K, Goldfarb DM, Haney J, Amat JAR, Herder V, Stewart M, et al. Human Rhinovirus Infection
 Blocks Severe Acute Respiratory Syndrome Coronavirus 2 Replication Within the Respiratory Epithelium:
 Implications for COVID-19 Epidemiology. J Infect Dis. 2021;224(1):31-8.

521 20. Essaidi-Laziosi M, Alvarez C, Puhach O, Sattonnet-Roche P, Torriani G, Tapparel C, et al. 522 Sequential infections with rhinovirus and influenza modulate the replicative capacity of SARS-CoV-2 in 523 the upper respiratory tract. Emerging Microbes & Infections. 2022;11(1):413-24.

524 21. Waterlow NR, van Leeuwen E, Davies NG, Group CC-W, Flasche S, Eggo RM. How immunity from 525 and interaction with seasonal coronaviruses can shape SARS-CoV-2 epidemiology. Proceedings of the 526 National Academy of Sciences. 2021;118(49):e2108395118.

527 22. Wratil PR, Schmacke NA, Karakoc B, Dulovic A, Junker D, Becker M, et al. Evidence for increased 528 SARS-CoV-2 susceptibility and COVID-19 severity related to pre-existing immunity to seasonal 529 coronaviruses. Cell Rep. 2021;37(13):110169.

530 23. Chin T, Foxman EF, Watkins TA, Lipsitch M. Considerations for viral co-infection studies in human 531 populations. mBio. 2024;15(7):e00658-24.

532